We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

IFN‐γ Release Assay Helps Diagnose Hemophagocytic Lymphohistiocytosis

By LabMedica International staff writers
Posted on 14 Aug 2020
Print article
The QuantiFERON‐TB Gold Plus IFN‐γ release assay used to help diagnose hemophagocytic lymphohistiocytosis (Photo courtesy of Qiagen).
The QuantiFERON‐TB Gold Plus IFN‐γ release assay used to help diagnose hemophagocytic lymphohistiocytosis (Photo courtesy of Qiagen).
Hemophagocytic lymphohistiocytosis (HLH), either primary (pHLH, or Familiar, FHL) or secondary is a life‐threatening hyper‐inflammatory syndrome, characterized by massive and uncontrolled activation of macrophages and T cells, causing fever, cytopenia and liver dysfunction with coagulopathy.

The rarity of the HLH disease, along with its pleomorphic clinical presentation that mimics a number of different conditions (from severe infections to malignancies), makes the diagnosis challenging. Hemophagocytosis on bone morrow biopsy is the only histomorphological criterion, but, in itself, it is neither specific nor sensitive.

Hematologists at the Bambino Gesù Children's Hospital (Rome, Italy) diagnosed and treated 13 children with pHLH at the hospital from August 2014 to April 2020. During the diagnostic evaluation, all patients were tested for tuberculosis (TB) exposure through QuantiFERON‐TB Gold (QFT‐G, Qiagen, Hilden, Germany). The QuantiFERON test is an IFN‐γ release assay (IGRA), which measures IFN‐γ release in response to tuberculosis (TB)‐specific antigens. After centrifugation, plasma was harvested and enzyme‐linked immunosorbent assay (ELISA) tests were run.

The scientists reported that results obtained from the HLH group (all tests were reported as ‘Indeterminate’ because of high levels of IFN‐γ in the NIL Tube) were compared with three other groups of pediatric patients (matched for gender) with an available QFT‐G. These groups were: 13 children hospitalized for acute leukemia (AL) at time of diagnosis, 13 because of sepsis and 13 healthy controls (HC). The median (range) IFN‐γ levels at diagnosis/before starting treatment in the HLH group was 2.49 IU/mL (0.12–15.11) , significantly higher than those found in the AL, sepsis and HC groups, in which the median (range) value was 0.04 IU/mL (0.02–0.11) 0.07 (IU/mL 0.03–0.15) and 0.036 IU/mL (0.015–0.077) , respectively. A cut‐off value of 0.12 IU/mL had a sensitivity of 100% and a specificity of 97.3%.

The authors concluded that QFT‐G Plus, a diffuse and standardized blood test, in association with HLH‐04 criteria could support clinicians in determining a diagnosis of pHLH with high sensitivity and specificity. Although other interferonopathies, genetic or acquired, such as systemic lupus erythematosus and juvenile dermatomyositis, could impair the specificity of the analysis, this simple diagnostic test could really support pediatricians in peripheral hospitals. The study was published on July 26, 2020 in the British Journal of Haematology.

Related Links:

Bambino Gesù Children's Hospital
Qiagen

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more

Industry

view channel
Illustration

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.